First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Presentazione di PowerPoint
Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Goede V et al. Proc EHA 2018;Abstract S ppt download
JANSSEN | Business Wire
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
The role of MRD in CLL
The role of MRD in CLL
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
IMBRUVICA® IN chronic lymphocytic leukaemia (CLL): experience you can rely on<sup>1-5</sup>
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
PDF) First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
PDF) The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Goede V et al. Proc EHA 2018;Abstract S ppt download
PCYC 2014.12.31 - 10-K
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
